Jaundice or hyperbilirubinaemia is a common complication of sepsis. UGT1A1 (UDP-glucuronosyltransferase 1A1) is a critical gene for bilirubin metabolism and irinotecan detoxification. However, the molecular pathogenesis of hyperbilirubinaemia during inflammation needs to be further clarified. Human hepatic UGT1A1 expression was analysed by RT (reverse transcription)-PCR, qRT-PCR (quantitative real-time PCR) and Western blotting in response to LPS (lipopolysaccharide) stimulation. Transcription regulatory elements in the upstream promoter region of the human UGT1A1 gene were determined using EMSA (electrophoretic mobility-shift assay) and ChIP (chromatin immunoprecipitation). The important role of the transcription regulatory element was examined using a luciferase assay, and was determined by qRT-PCR using a transcription factor activation inhibitor. LPS down-regulated the UGT1A1 mRNA expression in human hepatoma cell lines. A newly identified NF-κB (nuclear factor κB)-binding site was located on the upstream promoter region ( − 725/ − 716) of the human UGT1A1 gene. LPS-induced NF-κB activation and specific binding to the NF-κB-binding site can suppress human UGT1A1 promoter activity and human UGT1A1 expression. We demonstrated that LPS mediates the suppression of human UGT1A1 expression through specific binding of NF-κB to this newly identified NF-κB-binding site in the upstream promoter of the human UGT1A1 gene. The present study may partly explain the molecular pathogenesis of inflammation-associated hyperbilirubinaemia.
INTRODUCTION
UGT1A1 (UDP-glucuronosyltransferase 1A1) is a key enzyme, which is essential in the glucuronidation process for bilirubin metabolism and irinotecan detoxification [1] . The human UGT1A1 gene is located on chromosome 2q37, and UGT1A1 protein is encoded by alternative splicing of a unique exon 1 and common exons 2-5 [2, 3] . The expression of the human UGT1A1 gene is found in the liver, bile ducts, stomach and colon [1] , but the glucuronidation process is carried out mainly in the liver [4] . Genetic defects in the human UGT1A1 gene are responsible for congenital unconjugated hyperbilirubinaemia. Crigler-Najjar syndrome types I and II result from absent and severely reduced UGT1A1 activity respectively [1, 5] . In contrast, Gilbert's syndrome is characterized by unconjugated hyperbilirubinaemia caused by a mild decrease in UGT1A1 activity [6, 7] .
Genetic mutations in the core promoter and enhancer of the human UGT1A1 gene affect UGT1A1 activity. A wild-type TATA box [A(TA) 6 TAA] is located between − 39 and − 24 bp from the transcriptional start site of the human UGT1A1 gene. The dinucleotide polymorphism of A(TA) 7 TAA in the TATA box reduces the binding affinity of TBP (TATA-box-binding protein), causing a decrease in UGT1A1 transcription [8] . Transcription of the human UGT1A1 gene can be enhanced by the binding of transcription factors to the PBREM (phenobarbital-responsive enhancer module) [9] [10] [11] . PBREM is located between − 3499 and − 3210 bp in the upstream promoter of the human UGT1A1 gene [10] . A common genetic mutation, − 3263T>G, has been found in PBREM, which is associated with hyperbilirubinaemia in patients with Gilbert's syndrome [12] .
Jaundice or hyperbilirubinaemia is a common manifestation of sepsis. Sepsis-related jaundice in patients with bacterial infection has been reported [13, 14] . The pathogenesis of hyperbilirubinaemia is considered to be associated with abnormal bilirubin metabolism [15] . Inflammatory cholestasis is mainly caused by the inhibition of transporter expression and function in the liver [16] . Pro-inflammatory cytokines released by Kupffer cells are able to down-regulate the expression of transporters such as NTCP (sodium/taurocholate co-transporter), OATP (organic anion-transporting protein), BSEP (bile-salt-export pump) and MRP2 (canalicular conjugate export pump), resulting in inflammation-induced cholestasis [15] [16] [17] . The reduction of OATP and MRP2 leads to the accumulation of bilirubin in the body and results in hyperbilirubinaemia, which may cause cellular toxicity when it is severe [18, 19] . LPS (lipopolysaccharide), an endotoxin, is derived from the outer membrane of Gram-negative bacteria, which are considered the main aetiology of sepsis [20] . NF-κB (nuclear factor κB), a critical transcription factor, is involved in the regulation of gene expression in LPS-induced inflammation [21] . NF-κB is kept in an inactive form in the cytoplasm by interacting with IκB (inhibitor of NF-κB), which blocks its nuclear localization [22] . IκB is phosphorylated by IκB kinase and ubiquitinated in response to inflammatory stimuli, leading to its degradation by the proteasome [23] . The released NF-κB translocates to the nucleus, binds to and modulates its target genes in response to inflammatory stimuli [24, 25] .
Previous studies have shown the suppression of UGT1A1 expression in human and mouse liver in response to inflammation [26, 27] . However, the molecular mechanism of inflammationassociated down-regulation of UGT1A1 expression remains unknown. In the present study, we demonstrate that a reduction in human UGT1A1 expression was observed in response to LPS stimulation through the specific binding of NF-κB to a newly identified NF-κB-binding site in the upstream promoter region of the human UGT1A1 gene.
EXPERIMENTAL

Reagents
LPS from Escherichia coli (serotype O111:B4) was purchased from Sigma-Aldrich, and was dissolved in culture medium to 1 mg/ml and stored at − 20
• C. The NF-κB activation inhibitor JSH-23 (catalogue number sc-222061) was purchased from Santa Cruz Biotechnology, and was dissolved in DMSO (SigmaAldrich) to 10 mg/ml and stored at − 20
• C.
Animal studies
C57BL/6J mice at 7 weeks old were injected intraperitoneally with 1 mg of LPS/kg of body weight which was dissolved in sterile 0.9 % saline or saline as a control (six mice per group, n = 6). All mice were killed at 16 h after injection and their livers and blood were collected, and then all samples were stored at − 80 • C until use. Mouse serum was prepared and measured for TB (total bilirubin) and CB (conjugated bilirubin) using a bilirubin assay kit (Abnova) according to the manufacturer's instructions, or for AST (aspartate aminotransferase) and ALT (alanine aminotransferase) by the National Laboratory Animal Center (Taipei, Taiwan, R.O.C.). Data were shown as the means + − S.D. from six mice per group. All experiments were approved by the Institutional Animal Care and Use Committee of the National Defense Medical Center and were conducted in accordance with the institution's guidelines.
Cell culture and transfection
Human hepatoma cell lines, Huh7 and HepG2 cells, were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % heat-inactivated fetal bovine serum (Hyclone). Cells were cultured at 37
• C in a humidified incubator containing 5 % CO 2 . Plasmids were transfected into cells using GenJet In Vitro DNA Transfection Reagent version II (SignaGen Laboratories) following the manufacturer's instructions.
Plasmid construction
The upstream promoter sequence between − 1500 and − 1 from the transcriptional start site of the human UGT1A1 gene was amplified by PCR from human genomic DNA and cloned into the XhoI site of pGL3-Basic vector (Promega), yielding pGL3/wild-type human UGT1A1 promoter construct. Primers used for cloning the wild-type promoter were: forward, 5 -GGAATTCTCGAGTGGGATCTGTGCAGTTATCT-3 ; and reverse, 5 -GGAATTCTCGAGGCCAGAGGTTCGCCCTCTCC-3 . The NF-κB-binding site deletion mutant luciferase reporter vector was generated by PCR and ligation of two pieces of DNA fragments, and cloned into the XhoI site of pGL3-Basic vector, yielding pGL3/deletion mutant human UGT1A1 promoter construct. Primer pairs used for cloning the deletion mutant promoter were: forward, 5 -CTTTCTGGTCATT-CTCTACCCCAG-3 ; and reverse, 5 -GGAATTCTCGAG-GCCAGAGGTTCGCCCTCTCC-3 ; and forward, 5 -GGAATT-CTCGAGTGGGATCTGTGCAGTTATCTTG-3 ; and reverse, 5 -TGGAGCGCATGTGAACAGAA-3 . The putative GATA2-binding site deletion mutant luciferase reporter vector was generated as described above. Primer pairs used for cloning this deletion mutant promoter were: forward 5 -GAAACT-TGCTTAGTTCTTATTGGTC-3 ; and reverse, 5 -GGAA-TTCTCGAGGCCAGAGGTTCGCCCTCTCC-3 ; and forward, 5 -GGAATTCTCGAGTGGGATCTGTGCAGTTATCTTG-3 ; and reverse 5 -TCATTTGCATAAATGGACCT-3 . The XhoI site is underlined.
RNA extraction
Total RNA was isolated using TRIzol ® (Invitrogen) according to the manufacturer's instructions, and genomic DNA was further removed using the Turbo DNA-free kit (Applied Biosystems).
RT (reverse transcription)-PCR
Total RNA was subjected to RT using the ImProm-II Reverse Transcription System (Promega) following the manufacturer's instructions. Expression of mouse and human UGT1A1 mRNA was determined by RT-PCR. The PCR conditions were as follows: 94
• C for 2 min, then 30 cycles of 94 • C for 30 s, 52
• C for 1 min, and 72
• C for 1 min using GoTaq Flexi DNA Polymerase (Promega). PCR products were electrophoresed in 1 % agarose gel. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal control. The primer sequences for mouse/human UGT1A1 and GAPDH genes have been described previously [27, 28] .
qRT-PCR (quantitative real-time PCR)
The cDNA was generated as described above. Expression of human UGT1A1 mRNA was determined by qRT-PCR using the Applied Biosystems 7500 Real-Time PCR system. 18S RNA was used as an internal control to normalize the amount of human UGT1A1 mRNA in each sample. The primer sequences for the human UGT1A1 gene and 18S RNA have been described previously [26] . Cycle threshold values were calculated using the SDS software v1.4 using automatic baseline settings and threshold. Significant difference of relative gene expression was determined using the 2 − C T method [29] .
Database analysis
The upstream promoter sequence of the mouse and human UGT1A1 gene was analysed using the TRED (Transcriptional Regulatory Element Database) provided by the Michael Zhang laboratory, Cold Spring Harbor Laboratory (http://rulai.cshl.edu/ cgi-bin/TRED/tred.cgi?process=analysisMatrixForm).
EMSA (electrophoretic mobility-shift assay)
Preparation of nuclear extracts
Nuclear extracts from mouse liver were prepared using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific) according to the manufacturer's instructions. Nuclear extracts were stored at − 80
• C until use.
Preparation of the biotin end-labelled probe
The probe was prepared using the Biotin 3 End DNA Labeling kit (Thermo Scientific) following the manufacturer's instructions. For EMSA, the biotin-labelled double-stranded DNA probe was prepared by mixing together equal amounts of labelled complementary oligonucleotides and incubating the mixture for 1 h at room temperature (25 • C).
Binding reactions and electrophoresis
Binding reactions and electrophoresis were performed using the LightShift Chemiluminescent EMSA kit (Thermo Scientific) according to the manufacturer's instructions. Briefly, the binding reaction was incubated at room temperature for 20 min in a total volume of 20 μl containing nuclear extracts or recombinant NF-κB protein (Promega), biotin-end-labelled probes, 1× binding buffer, 10 % (v/v) glycerol, 0.05 % Nonidet P40, 0.1 mM EDTA and 50 ng/ml poly(dI-dC) · (dI-dC), and an anti-NF-κB antibody for super-shift analysis. In competition analysis, the binding reaction was performed with the addition of a 50-or 100-fold excess of unlabelled probes. Each binding reaction was analysed on a 6 % polyacrylamide gel, and then transferred on to a nylon membrane (Amersham) with exposure to UV light to facilitate cross-linking.
Detection of the biotin-labelled probe
The biotin-labelled probe was detected using the LightShift Chemiluminescent EMSA kit (Thermo Scientific) following the manufacturer's instructions.
ChIP (chromatin immunoprecipitation) assay
The ChIP assay was performed using the Chromatin Immunoprecipitation Assay kit (Millipore). An anti-NF-κB antibody (Santa Cruz Biotechnology) was used in the ChIP assay. The eluted DNA was purified with phenol/chloroform and a fraction was used as the PCR template to detect the presence of NF-κB-binding sequences. Primers used for detecting NF-κB-binding sequences ( − 725/ − 716) were: forward, 5 -AAAATCTCAACTATAAAAAGG-3 ; and reverse, 5 -GAGTCCAGCACAGTGTGGGG-3 . The PCR conditions were as follows: 94 • C for 2 min, then 30 cycles of 94 • C for 30 s, 52
• C for 1 min and 72
• C for 1 min using GoTaq Flexi DNA Polymerase (Promega). PCR products were electrophoresed in 1 % agarose gel.
Luciferase reporter assay
Cells were transfected with luciferase reporter vectors. All transfections included pRL-TK vector (Promega) for normalization. Luciferase activities were measured at 24 h after transfection using the Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions. Renilla luminescence, expressed from the pRL-TK vector, was used as an internal control to normalize the luciferase activity.
Western blotting
Cell lysates were extracted using RIPA buffer (Sigma). Nuclear proteins from cells were extracted using NE-PER nuclear and cytoplasmic extraction reagents (Thermo Scientific) as described above. Cell lysates and nuclear protein were electrophoresed on SDS/PAGE (8% gels) and electroblotted on to PVDF membranes (Millipore). Anti-UGT1A1 (Abcam), anti-MRP2 (Abcam), anti-OATP (Abcam), anti-NF-κB, anti-β-actin (Sigma) and anti-TBP antibodies (Santa Cruz Biotechnology) were used in Western blotting. TBP was used as an internal control.
Statistical analysis
Data are shown as the means + − S.D. from triplicate experiments. The two-sided Student's t test was used for comparisons between experimental groups. P < 0.05 was considered statistically significant.
RESULTS
LPS down-regulates UGT1A1 expression in mouse liver and human hepatoma cell lines
LPS administration is an experimental model of infection and inflammation in mice. To examine the effect of LPS on mouse liver, mice were injected with LPS (1 mg/kg of body weight) or saline. Mouse serum was collected at 16 h after injection, and then was measured for serum TB, CB, UCB (unconjugated bilirubin), AST and ALT. The results showed that hepatic dysfunction with an elevation of AST (122.5 + − 4.9 compared with 56.2 + − 4. Figure 1A , left-hand panels). Normal ranges of TB, AST and ALT in mice are <0.5 mg/dl, <100 units/l and <100 units/l respectively. The elevation of serum TB suggested that abnormal bilirubin metabolism, such as decreased clearance of CB, may lead to hyperbilirubinaemia during inflammation. To determine the effect of LPS on mouse UGT1A1 expression, we analysed hepatic UGT1A1 expression in mice injected with or without LPS by RT-PCR and Western blotting. The results showed that mouse hepatic UGT1A1 expression at mRNA and protein levels was significantly inhibited after LPS treatment ( Figure 1A , right-hand panels). OATP and MRP2 are known to mediate hepatic uptake and excretion of UCB and CB, respectively. As confirmed by Western blotting, OATP expression was not affected; however, MRP2 expression was slightly inhibited by LPS stimulation ( Figure 1A , bottom righthand panel). These results suggested that the reduction of UGT1A1 and MRP2 expression by LPS stimulation leads to hyperbilirubinaemia in vivo. This result is consistent with the observation by Richardson et al. [27] . In humans, a previous study has shown the suppression of hepatic UGT1A1 mRNA expression in patients with chronic hepatitis, suggesting that hepatic UGT1A1 expression is reduced while the liver is inflamed [26] . Some studies have reported hyperbilirubinaemia in patients with bacterial infection [13, 14] . To clarify the mechanism of bacterial infection-mediated hyperbilirubinaemia, we used LPS as an experimental model of inflammation in the human hepatoma cell lines Huh7 and HepG2. To determine the effect of LPS on human UGT1A1 expression, Huh7 and HepG2 cells were treated with or without LPS (100 μg/ml) for 24 h and then UGT1A1 expression was examined by RT-PCR and Western blotting. The results showed that UGT1A1 mRNA expression was reduced in response to LPS stimulation in Huh7 and HepG2 cells ( Figure 1B , top left-hand panel). In addition, as confirmed by qRT-PCR and Western blotting, UGT1A1 expression at the mRNA and protein levels was reduced with the increased amount of LPS in Huh7 and HepG2 cells ( Figure 1B , top right-hand and bottom panels). Our results are consistent with previous studies that show the down-regulation of UGT1A1 expression in human and mouse livers in response to inflammation [26, 27] . Together, these data demonstrate that LPS suppresses UGT1A1 expression in mouse liver and human hepatoma cell lines. (Figure 2A, bottom left-hand panel, lanes 3 and 4) . The consensus and putative NF-κB-binding sites are underlined. We further determined the specific binding and the binding affinity of NF-κB to the − 725/ − 716-containing probe (5 -GCTCCAGTGAATTTCCCTTTCT-3 ) by EMSA and competitive EMSA analysis. The result showed that the specific binding of NF-κB decreased with an increased amount of wildtype non-labelled competitor (Figure 2A , bottom right-hand panel, lanes 2, 3 and 4). In contrast, the specific binding of NF-κB to the wild-type probe was not affected by the mutant non-labelled competitor (5 -GCTCCAGTCAAATTGCCTTTCT-3 ) (Figure 2A , bottom right-hand panel, lanes 2, 5 and 6). The three mutated sites are indicated in bold. To assess NF-κB activation induced by LPS, Huh7 and HepG2 cells were treated with the increased amount of LPS for 24 h and we examined the nuclear translocation of NF-κB by Western blotting. The results showed that the nuclear translocation of NF-κB in Huh7 and HepG2 cells was induced in response to increasing amounts of LPS stimulation ( Figure 2B , top panels). To confirm further that NF-κB was brought to the NF-κB-binding site ( − 725/ − 716) in the human UGT1A1 promoter, Huh7 and HepG2 cells were treated with LPS (100 μg/ml) for 24 h and then the specific binding of NF-κB was examined by ChIP assay. The results showed the specific binding of NF-κB to the − 725/ − 716-containing DNA fragment in Huh7 and HepG2 cells ( Figure 2B , bottom panels), demonstrating that NF-κB can bind to the NF-κB-binding site ( − 725/ − 716) in the human UGT1A1 promoter. The identified NF-κB-binding sequence ( − 725/ − 716) from the human UGT1A1 promoter was aligned with the consensus NF-κB-binding sequence based on software from LALIGN (http://www.ch.embnet.org/software/LALIGN_form.html) (Figure 2C, left-hand panel) . The position of this newly identified NF-κB-binding site in the human UGT1A1 promoter is shown in Figure 2 (C), right-hand panel. Taken together, these data demonstrate that NF-κB can specifically bind to a newly identified NF-κB-binding site ( − 725/ − 716) in the upstream promoter of the human UGT1A1 gene.
In the mouse Ugt1a1 promoter region, four putative NF-κB-binding sites were found using the TRED ( Figure 2D , left-hand panel). To examine the specific binding of NF-κB, four probes for the DNA fragments containing − 587/ − 578, − 492/ − 483, − 625/ − 616 and − 303/ − 294 respectively, were synthesized and analysed by super-shift assay. The result showed that a super-shift band was observed after treatment with the − 587/ − 578-containing probe with the anti-NF-κB antibody and nuclear extracts from LPS-stimulated mouse liver ( Figure 2D,  right-hand panel) . This result suggests that the NF-κB protein specifically binds to the upstream promoter of the mouse Ugt1a1 gene.
LPS down-regulates UGT1A1 expression through NF-κB activation and the presence of the NF-κB-binding site in the human UGT1A1 promoter
To determine the importance of NF-κB in LPS-mediated downregulation of human UGT1A1 expression, Huh7 and HepG2 cells were treated with an increased amount of the NF-κB activation inhibitor JSH-23 for 24 h in response to LPS stimulation (100 μg/ml). The UGT1A1 mRNA expression and the nuclear translocation of NF-κB were examined by qRT-PCR and Western blotting respectively. The results showed that JSH-23 inhibited the nuclear translocation of NF-κB induced by LPS in Huh7 and HepG2 (Figure 3 Figure 4A , bottom panels, fifth and sixth bars). The magnitude of decrease in promoter activity in luciferase activity assay using the promoter region ( − 1000/ − 1) is much smaller than that in mRNA expression in response to LPS. This observation suggests that other ciselements may be involved in LPS-induced UGT1A1 suppression. Therefore we searched the promoter region upstream of the NF-κB-binding site using the TRED. A putative GATA2-binding site (GGATG, − 1045/ − 1041) was found in the human UGT1A1 upstream promoter region. GATA2 has been reported to cooperate with NF-κB in down-regulation of erythropoietin gene (EPO) expression [30, 31] . We then constructed three luciferase reporter vectors for promoter activity analysis ( Figure 4B , lefthand panel). One luciferase reporter vector contained a wildtype UGT1A1 promoter sequence ( − 1/ − 1500) followed by the luciferase gene. One construct contained a UGT1A1 promoter sequence without the NF-κB-binding sequence ( − 725/ − 716) followed by the luciferase gene. The other construct contained a UGT1A1 promoter sequence without a putative GATA2-binding site followed by the luciferase gene. We demonstrated that the promoter activities of the deletion mutants and the wild-type UGT1A1 promoter were not affected in Huh7 and HepG2 cells without LPS stimulation (results not shown). In this context, the results showed that the promoter activity of the wild-type UGT1A1 was significantly reduced by LPS compared with control without LPS treatment in Huh7 and HepG2 cells ( Figure 4B , right-hand panel, first, second and third bar pairs). The luciferase activities had a maximum reduction of 60 % in Huh7 cells and that of 65 % GTCCTTGGGGAAGACTTCTGTT-3 ) . The NF-κB binding site is underlined. NF-κB specifically bound to the wild-type NF-κB-binding probe (bottom right-hand panel). Wild-type (5 -GCTCCAGTGAATTTCCCTTTCT-3 ) or mutant (5 -CTCCAGTAAACTTACCTTTC-3 ) with three mutant sites NF-κB-binding sequence was used as a probe. The NF-κB-binding site is underlined and the three mutant sites are indicated in bold. (B) LPS-activated and -induced nuclear translocation of NF-κB in Huh7 and HepG2 cells (top panels). The nuclear translocation of NF-κB was determined by Western blotting in response to LPS stimulation in a dose-dependent manner. TBP served as an internal control. The ChIP assay was performed using LPS-treated Huh7 or HepG2 cell lysates and an antibody against NF-κB (bottom panels). DNA derived from aliquots of cell lysates is labelled Input. IgG served as an internal control. in HepG2 cells after LPS stimulation (100 μg/ml). However, the promoter activity of the NF-κB-binding site deletion mutant was not significantly affected by LPS in Huh7 and HepG2 cells ( Figure 4B , right-hand panel, fourth, fifth and sixth bar pairs). It is reported that IL (interleukin)-1β and TNF-α (tumour necrosis factor α) mediated the suppression of erythropoietin expression through the direct DNA binding of NF-κB and GATA2 to their binding sites in the upstream promoter of the erythropoietin gene [31] . In the present study, we showed that the reduction in the promoter activity of the GATA2-binding site deletion mutant is smaller than that in the promoter activity of the wild-type UGT1A1 promoter ( − 1/ − 1500) in Huh7 and HepG2 cells after LPS stimulation ( Figure 4B , right-hand panel, second, third, eighth and ninth bar pairs). This result suggested that NF-κB may cooperate with GATA2 in LPS-mediated down-regulation of human UGT1A1 expression. As we have shown in Figures 2(B) and 2(C), NF-κB can specifically bind to the newly identified NF-κB-binding site ( − 725/ − 716) in the human UGT1A1 promoter. Taken together, these data demonstrate that NF-κB activation and specific binding to the NF-κB-binding site ( − 725/ − 716) are required for LPS-mediated down-regulation of human UGT1A1 expression.
DISCUSSION
In the present study, we demonstrate that LPS mediates the down-regulation of human UGT1A1 expression through specific binding of NF-κB to a newly identified NF-κB-binding site in the upstream promoter of the human UGT1A1 gene.
NF-κB is able to suppress its target genes, although it is generally considered to be a transcriptional activator. NF-κB mediates transcriptional repression of its target genes either through the induction of a transcriptional repressor, which in turn suppresses the target gene, or through the direct binding to the target gene [31] [32] [33] [34] [35] . For example, NF-κB can indirectly repress the expression of the MyoD gene through the transcriptional repressor YY1 (Yin Yang 1) [32, 33] . NF-κB (p65/p50) induces the expression of the YY1 gene through direct binding to the NF-κB-binding site in the YY1 upstream promoter. YY1, in turn, directly represses the expression of the MyoD gene by the direct binding to the YY1-binding site in its upstream promoter [32, 33] . The second possible way by which NF-κB mediates suppression is through direct binding to the NF-κB-binding site in the upstream promoter of its target genes. Hou et al. [34] have shown that the NF-κB-binding site exists in the negative regulatory element (ε-NRAII) in the upstream promoter of the human ε-globin gene, suggesting that NF-κB may down-regulate human ε-globin expression through direct binding to ε-NRAII. Another example comes from the transcriptional repression of the microRNA let-7i. O'Hara et al. [35] demonstrated that the NF-κB p50-C/EBPβ (CCAAT/enhancer-binding protein β) complex binds to the transcription regulatory element in the upstream promoter, resulting in the transcriptional repression of the microRNA let-7i. In addition, the suppression of erythropoietin expression by the pro-inflammatory cytokines IL-1β and TNF-α is also mediated through the direct DNA binding of NF-κB and GATA-2 to their binding sites in the upstream promoter of the erythropoietin gene [31] . In the present study, one putative GATA2-binding site (GGATG, − 1045/ − 1041) in the human UGT1A1 promoter region was found using TRED. The promoter activity assay of the deletion mutant suggested that the co-operation between NF-κB and GATA2 performed the down-regulation of human UGT1A1 expression in response to LPS stimulation.
NF-κB activation plays a key role in LPS-induced inflammation. LPS binds to LBP (LPS-binding protein) produced by hepatocytes to form a complex [36] [37] [38] . The LPS-LBP complex can promote the transfer of LPS to CD14 on the cell membrane followed by NF-κB activation through TLR4 (Tolllike receptor 4), resulting in the modulation of NF-κB target genes [36] . Hepatocytes can express the soluble form of CD14 (sCD14), which can mediate NF-κB activation in CD14-negative cells in response to LPS stimulation [36, 39, 40] . In the present study, LPSmediated NF-κB activation and down-regulation of the human UGT1A1 gene in Huh7 and HepG2 cells demonstrates the direct effect of LPS on hepatocytes. LPS-mediated down-regulation of human UGT1A1 expression may occur through direct hepatocyte stimulation or through Kupffer cell activation. Activated Kupffer cells can produce pro-inflammatory cytokines such as IL-1 and TNF-α which are able to activate NF-κB [41, 42] . In the present study, we demonstrate that NF-κB activation is involved in the down-regulation of human UGT1A1 expression.
Human UGT1A1 expression is associated with the activation of NF-κB. The expression of the human UGT1A1 gene can be augmented when NF-κB translocation or DNA binding is inhibited. In previous studies, the flavonoid apigenin has been shown to be able to induce UGT1A1 expression in HepG2 and CaCo-2 cells [43, 44] . This induction is significantly augmented in the presence of an NF-κB translocation inhibitor [43, 44] . Furthermore, sulforaphane, an NF-κB DNA-binding inhibitor, can induce the expression of the UGT1A1 gene in HT29, HepG2 and CaCo-2 cells [44] [45] [46] . An NF-κB translocation inhibitor can also enhance the effect of sulforaphane on the induction of UGT1A1 expression [44] . These observations suggest that NF-κB activation is involved in the suppression of human UGT1A1 expression. In the present study, consistent with previous observations, our results demonstrate the important role of NF-κB activation in LPS-mediated down-regulation of human UGT1A1 expression.
In conclusion, in the present study, a novel NF-κB-binding site is identified in the upstream promoter of the human UGT1A1 gene. NF-κB activation and specific binding to this newly identified NF-κB-binding site are involved in the down-regulation of human UGT1A1 expression during LPS stimulation. This molecular mechanism may contribute to the important consequence of bilirubin metabolism and irinotecan detoxification during inflammation. Taken together, the present study may explain, in part, the molecular pathogenesis of hyperbilirubinaemia during inflammation ( Figure 5 ).
